Published online before print August 23, 2004, doi: 10.1161/01.CIR.0000140262.20831.8F
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:1134-1139.)
© 2004 American Heart Association, Inc.
Original Articles |
Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans
From the Departments of Cell Biology (M.-L.B., S.A.M., M.H.S., M.S.P., S.L.H.) and Cardiovascular Medicine (M.S.P., M.G., S.L.H.) and Center for Cardiovascular Diagnostics and Prevention (M.-L.B., S.A.M., M.H.S., M.S.P., S.L.H.), Cleveland Clinic Foundation, Cleveland, Ohio, and the Evans Department of Medicine and Whitaker Cardiovascular Institute (N.G., J.F.K., J.A.V.), Boston University School of Medicine, Boston, Mass.
Correspondence to Stanley L. Hazen, MD, PhD, Preventive Cardiology, Cleveland Clinic Foundation, 9500 Euclid Ave, C51, Cleveland, OH 44195. E-mail hazens{at}ccf.org
Received January 17, 2004; de novo received March 4, 2004; revision received May 2, 2004; accepted May 19, 2004.
Background— In vitro and animal studies demonstrate that myeloperoxidase catalytically consumes nitric oxide as a substrate, limiting its bioavailability and function. We therefore hypothesized that circulating levels of myeloperoxidase would predict risk of endothelial dysfunction in human subjects.
Methods and Results— Serum myeloperoxidase was measured by enzyme-linked immunoassay, and brachial artery flow-mediated dilation and nitroglycerin-mediated dilation were determined by ultrasound in a hospital-based population of 298 subjects participating in an ongoing study of the clinical correlates of endothelial dysfunction (age, 51±16; 61% men, 51% with cardiovascular disease). A strong inverse relation between brachial artery flow-mediated dilation and increasing quartile of serum myeloperoxidase level was observed (11.0±6.0%, 9.4±5.3%, 8.6±5.8%, and 6.4±4.5% for quartiles 1 through 4, respectively; P<0.001 for trend). Using the median as a cut point to define endothelial dysfunction, increasing quartile of myeloperoxidase predicted endothelial dysfunction after adjustment for classic cardiovascular disease risk factors, C-reactive protein levels, prevalence of cardiovascular disease, and ongoing treatment with cardiovascular medications (OR, 6.4; 95% CI, 2.6 to 16; P=0.001 for highest versus lowest quartile).
Conclusions— Serum myeloperoxidase levels serve as a strong and independent predictor of endothelial dysfunction in human subjects. Myeloperoxidase-mediated endothelial dysfunction may be an important mechanistic link between oxidation, inflammation, and cardiovascular disease.
Key Words: atherosclerosis • free radicals • inflammation • peroxidase • nitric oxide
This article has been cited by other articles:
 |
|
 |
|
  M. P. Kuligowski, R. Y. Q. Kwan, C. Lo, C. Wong, W. G. James, D. Bourges, J. D. Ooi, L. D. Abeynaike, P. Hall, A. R. Kitching, et al. Antimyeloperoxidase antibodies rapidly induce {alpha}4-integrin-dependent glomerular neutrophil adhesion Blood, June 18, 2009; 113(25): 6485 - 6494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-R. Liu, L. Tao, E. Gao, Y. Qu, W. B. Lau, B. L. Lopez, T. A. Christopher, W. Koch, T.-L. Yue, and X.-L. Ma Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation--a novel mechanism for the cardioprotective effects of PPAR agonists Cardiovasc Res, February 1, 2009; 81(2): 344 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Gandley, J. Rohland, Y. Zhou, E. Shibata, G. F. Harger, A. Rajakumar, V. E. Kagan, N. Markovic, and C. A. Hubel Increased Myeloperoxidase in the Placenta and Circulation of Women With Preeclampsia Hypertension, August 1, 2008; 52(2): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Heumuller, S. Wind, E. Barbosa-Sicard, H. H.H.W. Schmidt, R. Busse, K. Schroder, and R. P. Brandes Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant Hypertension, February 1, 2008; 51(2): 211 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Brevetti, V. Schiano, E. Laurenzano, G. Giugliano, M. Petretta, F. Scopacasa, and M. Chiariello Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease Eur. Heart J., January 2, 2008; 29(2): 224 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Meigs, M. G. Larson, C. S. Fox, J. F. Keaney Jr., R. S. Vasan, and E. J. Benjamin Association of Oxidative Stress, Insulin Resistance, and Diabetes Risk Phenotypes: The Framingham Offspring Study Diabetes Care, October 1, 2007; 30(10): 2529 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Meuwese, E. S.G. Stroes, S. L. Hazen, J. N. van Miert, J. A. Kuivenhoven, R. G. Schaub, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, et al. Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals: The EPIC-Norfolk Prospective Population Study J. Am. Coll. Cardiol., July 10, 2007; 50(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Q Khan, D. Kelly, P. Quinn, J. E Davies, and L. L Ng Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction Heart, July 1, 2007; 93(7): 826 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Mocatta, A. P. Pilbrow, V. A. Cameron, R. Senthilmohan, C. M. Frampton, A. M. Richards, and C. C. Winterbourn Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction J. Am. Coll. Cardiol., May 22, 2007; 49(20): 1993 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lavi, A. Prasad, E. H. Yang, V. Mathew, R. D. Simari, C. S. Rihal, L. O. Lerman, and A. Lerman Smoking Is Associated With Epicardial Coronary Endothelial Dysfunction and Elevated White Blood Cell Count in Patients With Chest Pain and Early Coronary Artery Disease Circulation, May 22, 2007; 115(20): 2621 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Exner, E. Minar, W. Mlekusch, S. Sabeti, J. Amighi, W. Lalouschek, G. Maurer, C. Bieglmayer, H. Kieweg, O. Wagner, et al. Myeloperoxidase Predicts Progression of Carotid Stenosis in States of Low High-Density Lipoprotein Cholesterol J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2212 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Capeillere-Blandin, V. Gausson, A. T. Nguyen, B. Descamps-Latscha, T. Drueke, and V. Witko-Sarsat Respective role of uraemic toxins and myeloperoxidase in the uraemic state Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1555 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Cameron, T. J. Mocatta, A. P. Pilbrow, C. M. Frampton, R. W. Troughton, A. M. Richards, and C. C. Winterbourn Angiotensin Type-1 Receptor A1166C Gene Polymorphism Correlates With Oxidative Stress Levels in Human Heart Failure Hypertension, June 1, 2006; 47(6): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fichtlscherer, C. Schmidt-Lucke, S. Bojunga, L. Rossig, C. Heeschen, S. Dimmeler, and A. M. Zeiher Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy Eur. Heart J., May 2, 2006; 27(10): 1182 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. T. Willerson, and P. M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Baldus, V. Rudolph, M. Roiss, W. D. Ito, T. K. Rudolph, J. P. Eiserich, K. Sydow, D. Lau, K. Szocs, A. Klinke, et al. Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase Circulation, April 18, 2006; 113(15): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Stenvinkel, E. Rodriguez-Ayala, Z. A. Massy, A. R. Qureshi, P. Barany, B. Fellstrom, O. Heimburger, B. Lindholm, and A. Alvestrand Statin Treatment and Diabetes Affect Myeloperoxidase Activity in Maintenance Hemodialysis Patients Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 281 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow High-Density Lipoprotein Function: Recent Advances J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1792 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Sullivan Stored Iron and Vascular Reactivity Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1532 - 1535. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Nicholls and S. L. Hazen Myeloperoxidase and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1102 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Coller Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality: Is It Time to Intervene? Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 658 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Walter, K. Schroecksnadel, D. Fuchs, J. A. Vita, J. F. Keaney Jr, N. Gokce, M.-L. Brennan, S. A. Mann, M. Goormastic, M. H. Shishehbor, et al. Letter Regarding Article by Vita et al, "Serum Myeloperoxidase Levels Independently Predict Endothelial Dysfunction in Humans" * Response Circulation, March 29, 2005; 111(12): e167 - e168. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Griendling ATVB In Focus: Redox Mechanisms in Blood Vessels Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 272 - 273. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zheng, M. Settle, G. Brubaker, D. Schmitt, S. L. Hazen, J. D. Smith, and M. Kinter Localization of Nitration and Chlorination Sites on Apolipoprotein A-I Catalyzed by Myeloperoxidase in Human Atheroma and Associated Oxidative Impairment in ABCA1-dependent Cholesterol Efflux from Macrophages J. Biol. Chem., January 7, 2005; 280(1): 38 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Marsche, R. Heller, G. Fauler, A. Kovacevic, A. Nuszkowski, W. Graier, W. Sattler, and E. Malle 2-Chlorohexadecanal Derived From Hypochlorite-Modified High-Density Lipoprotein-Associated Plasmalogen Is a Natural Inhibitor of Endothelial Nitric Oxide Biosynthesis Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2302 - 2306. [Abstract] [Full Text] [PDF]
|
|